China Pharmaceutical Sector Report 2017 4th Quarter

  • ID: 4483554
  • Report
  • Region: China
  • 60 pages
  • EMIS, A Euromoney Institutional Investor Company
1 of 5
As a Result of the Ongoing Environmental Inspection Campaign in Q3 2017 the Production Volume of Pharmaceutical and Medical Products Dropped by 1.5% Y/Y to 801,000 Tonnes

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE

This report provides a complete and detailed analysis of the pharmaceutical sector for China. The author presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:

  • Understand the key elements at play in the pharmaceutical sector in China
  • Assess market for growth in the sector
  • View key data on production and sales for the sector in China
  • Crystallise the forces both driving and restraining this sector in China
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in China
  • Build a clear picture of trends and issues for sub-sectors (western medicine, traditional Chinese medicine).
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE
1. Executive Summary
  • Sector in Numbers
  • Sector Overview
  • Sector Snapshot
  • Driving Forces
  • Restraining Forces
2. Sector in Focus
  • Quarterly Update
  • Quarterly Summary
  • Sector Outlook
  • Sector Highlights
  • Main Sector Indicators
  • Top M&A Deals
  • M&A Activity
3. Competitive Landscape
  • Highlights
  • Top Pharmaceutical Enterprises
  • Top Pharmaceutical Manufacturers
  • Top Pharmaceutical Exporters
  • To Listed Companies
4. Companies in Focus
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Nanjing Pharmaceutical Co Ltd
  • Huadong Medicine Co Ltd
  • China Meheco Co Ltd
  • Kangmei Pharmaceutical Co Ltd
5. Regulatory Environment
  • Government Policy
  • Healthcare Reform 2015
  • Sector Reform 2015-2016
  • Anti-Corruption Policies
6. Western Medicine
  • Highlights
  • Main Indicators by Segment
7. Traditional Chinese Medicine
  • Highlights
  • Main Indicators by Segment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • China Meheco Co Ltd
  • Huadong Medicine Co Ltd
  • MORE
In the third quarter of 2017, all subsectors of China’s pharmaceutical manufacturing sector, except the ready-prepared traditional Chinese medicines (TCMs), marked y/y growth in their revenues. The sizeable decline of 26.9% y/y in the TCM subsector’s revenue, however, had a negative impact on the whole sector’s revenue, which totalled RMB 726.2bn, down by 1.8% y/y. The sector’s total profit rose 15.9% to RMB 87.1bn, driven by the gradual implementation of the “two invoices” system. As a result of the ongoing environmental inspection campaign in Q3 2017 the production volume of pharmaceutical and medical products dropped by 1.5% y/y to 801,000 tonnes. The closure of a number of heavy-polluting producers of active pharmaceutical ingredients (APIs) caused a significant increase in API product prices. In Q3 2017 both the imports and the exports of pharmaceutical products marked y/y increases in value and volume terms. In this period the imports of pharmaceutical and medical products rose by 9.2% y/y to USD 6.5bn, while the exports increased by 9.1% y/y to USD 3.7bn. The number of pharmaceutical enterprises in China rose to 8,710 at the end of September 2017. Of these, 1,075 were loss making enterprises, compared to 1,119 at end-June and 1,373 at end-March 2017. The profitability of pharmaceutical manufacturers improved significantly after the implementation of the “two invoices” systems, which simplified drug supply chain and reduced distribution expenses.
Note: Product cover images may vary from those shown
5 of 5
  • Shanghai Pharmaceuticals Holding Co Ltd
  • Nanjing Pharmaceutical Co Ltd
  • Huadong Medicine Co Ltd
  • China Meheco Co Ltd
  • Kangmei Pharmaceutical Co Ltd
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll